Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control group) receiving sequentially Priorix (Month 0) and Infanrix (Month 6) vaccines.
Epistemonikos ID: 00e83ffeb8cbb33274dcab3b8966945f971907c5
First added on: Mar 23, 2020